Phase I trial of oral vorinostat (Suberoylanilide hydroxamic acid, SAHA) in combination with bortezomib in patients with advanced multiple myeloma

被引：15
|
作者：
Weber, Donna M. [1 ]
Jagannath, Sundar [2 ]
Mazumder, Amitabha [2 ]
Sobecks, Ronald [3 ]
Schiller, Gary J. [4 ]
Gavino, Maria [1 ]
Sumbler, Chantelle [1 ]
McFadden, Carrie [3 ]
Chen, Cong [5 ]
Ricker, Justin L. [5 ]
Rizvi, Syed [5 ]
Oerth, Carol [5 ]
Brownell, Patricia [5 ]
Husein, Mohamad A. [6 ]
机构：
[1] MD Anderson Canc Ctr, Houston, TX USA
[2] St Vincents Comprehens Canc Ctr, New York, NY USA
[3] Cleveland Clin Fdn, Cleveland, OH 44195 USA
[4] Univ Calif Los Angeles, Sch Med, Los Angeles, CA USA
[5] Merck Res Labs, Upper Gwynedd, PA USA
[6] H Lee Moffitt Canc Ctr & Res Inst, Tampa, FL USA
来源：
BLOOD | 2007年 / 110卷 / 11期
关键词：
D O I：
10.1182/blood.V110.11.1172.1172
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
1172
引用
收藏
页码：355A / 355A
页数：1
相关论文
共 50 条
  • [1] Phase I trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) in patients with advanced multiple myeloma
    Richardson, Paul
    Mitsiades, Constantine
    Colson, Kathleen
    Reilly, Eileen
    Mcbride, Laura
    Chiao, Judy
    Sun, Linda
    Ricker, Justin
    Rizvi, Syed
    Oerth, Carol
    Atkins, Barbara
    Fearen, Ivy
    Anderson, Kenneth
    Siegel, David
    LEUKEMIA & LYMPHOMA, 2008, 49 (03) : 502 - 507
  • [2] Final results of a phase I trial of oral vorinostat (Suberoylanilide hydroxamic acid, SAHA) in patients with advanced multiple myeloma
    Richardson, Paul G.
    Mitsiades, Constantine S.
    Colson, Kathleen
    Reilly, Eileen
    McBride, Laura
    Chiao, Judy
    Sun, Linda
    Ricker, Justin L.
    Rizvi, Syed
    Oerth, Carol
    Atkins, Barbara
    Fearen, Ivy
    Anderson, Kenneth C.
    Siegel, David S.
    BLOOD, 2007, 110 (11) : 357A - 357A
  • [3] PHASE I TRIAL OF ORAL VORINOSTAT IN COMBINATION WITH BORTEZOMIB IN ADVANCED MULTIPLE MYELOMA
    Weber, D. M.
    Jagannah, S.
    Mazumder, A.
    Sobecks, R.
    Schiller, G. J.
    Gavino, M.
    Meehan, K.
    McFadden, C.
    Chen, C.
    Ricker, J. L.
    Rizvi, S.
    Oerth, C.
    Brownell, P.
    Sanz-Rodriguez, C.
    Hussein, M. A.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2008, 93 : 257 - 257
  • [4] Phase I trial of vorinostat (suberoylanilide hydroxamic acid, SAHA) in patients with solid tumors
    Fujiwara, Yutaka
    Yamamoto, Noboru
    Yamada, Kazuhiko
    Yamada, Yasuhide
    Koizumi, Fumiaki
    Shimoyama, Tatsu
    Nishio, Kazuto
    Otsuki, Tetsuya
    Frankel, Stanley R.
    Tamura, Tomohide
    JOURNAL OF THORACIC ONCOLOGY, 2007, 2 (08) : S459 - S459
  • [5] Phase I trial of suberoylanilide hydroxamic acid (SAHA) plus bortezomib (Bort) in relapsed multiple myeloma (MM) patients (pts).
    Badros, Ashraf
    Philip, S.
    Niesvizky, R.
    Goloubeva, O.
    Harris, C.
    Zweibel, J.
    Wright, J.
    Burger, A.
    Grant, S.
    Baer, M. K.
    Egorin, M. J.
    BLOOD, 2007, 110 (11) : 354A - 354A
  • [6] A phase I study of vorinostat (suberoylanilide hydroxamic acid, SAHA) in Japanese patients with gastrointestinal (GI) cancer
    Chin, K.
    Hatake, K.
    Hamaguchi, T.
    Shirao, K.
    Doi, T.
    Noguchi, K.
    Garcia-Vargas, J. E.
    Ohtsu, A.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [7] Clinical responses to oral vorinostat (Suberoylanilide hydroxamic acid, SAHA) are associated with specific gene expression signatures in patients with advanced leukemias: Results of a phase I trial.
    Loboda, Andrey
    Fantin, Valeria R.
    Bueso-Ramos, Carlos E.
    Randolph, Sophia
    Hardwick, James S.
    Ricker, Justin L.
    Richon, Victoria M.
    Issa, Jean-Pierre
    Kantarjian, Hagop M.
    Frankel, Stanley R.
    Garcia-Manero, Guillermo
    BLOOD, 2006, 108 (11) : 657A - 657A
  • [8] Phase I clinical trial of oral administration of the histone deacetylase (HDAC) inhibitor suberoylanilide hydroxamic acid (SAHA) in patients with relapsed/refractory multiple myeloma
    Richardson, P
    Schlossman, RL
    Mitsiades, CS
    Munshi, NC
    Colson, K
    Doss, D
    McKenney, M
    Hande, K
    Gorelik, S
    Lunde, L
    Stepanek, A
    Freeman, A
    Dinand, K
    Hayes, S
    Michelle, R
    Doucet, K
    Warren, D
    Mitsiades, N
    Richon, VM
    Chiao, J
    Anderson, KC
    BLOOD, 2004, 104 (11) : 420A - 420A
  • [9] A phase I and pharmacokinetic/pharmacodynamic study of vorinostat (suberoylanilide hydroxamic acid, SAHA) in Japanese patients with solid tumor
    Fujiwara, Y.
    Yamamoto, N.
    Yamada, K.
    Yamada, Y.
    Shimoyama, T.
    Koizmi, F.
    Nishio, K.
    Otsuki, T.
    Frankel, S. R.
    Tamura, T.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [10] Phase I study of vorinostat (suberoylanilide hydroxamic acid [SAHA]) in combination with temozolomide in patients with malignant gliomas (NABTC 04-03)
    Wen, Patrick
    Puduvalli, Vinay
    Kuhn, John
    Reid, Joel
    Cloughesy, Timothy
    Yung, Wka
    Drappatz, Jan
    Lamborn, Kathleen
    Gilbert, Mark
    Butowski, Nicholas
    Levin, Victor
    Chang, Susan
    Kesari, Santosh
    Robbins, Hi
    McGovern, Renee
    Richon, Victoria
    Frankel, Stanley
    Ames, Matthew
    Zweibel, James
    Prados, Michael
    NEURO-ONCOLOGY, 2007, 9 (04) : 518 - 518
12345